EI
SYRE icon

Ellevest Inc’s Spyre Therapeutics SYRE Stock Holding History

Ellevest Inc’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6
Closed -$1K – 1575
2021
Q2 		$1K Buy
6
+1
+20% +$182 ﹤0.01% 1204
2021
Q1 		$1K Buy
5
+2
+67% +$384 ﹤0.01% 1205
2020
Q4 		$1K Hold
3
– – ﹤0.01% 1114
2020
Q3 		$1K Buy
+3
New +$555 ﹤0.01% 1065

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ellevest Inc's SYRE Position: Q3 2021 in Review

Ellevest Inc sold out of Spyre Therapeutics (SYRE) in Q3 2021, closing a stake of 6 shares — an estimated $1K sold.

Ellevest Inc first reported a position in SYRE in Q3 2020 and held it in 4 quarters. The position peaked at $1K in Q2 2021. 77 funds tracked by Wall St. Rank hold SYRE as of Q3 2021.

  • Ellevest Inc reported no remaining Spyre Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ellevest Inc sold 6 Spyre Therapeutics shares in Q3 2021, an estimated $1K.
  • Ellevest Inc first reported a position in Spyre Therapeutics in Q3 2020 and held it in 4 quarters.
  • Ellevest Inc's Spyre Therapeutics position peaked at $1K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2021.

Based on Ellevest Inc's 13F filing for Q3 2021, filed 19 Oct 2021.